Emergent BioSolutions (NYSE:EBS) Shares Down 7.1% – Time to Sell?

Emergent BioSolutions Inc. (NYSE:EBS)’s stock price traded down 7.1% on Tuesday . The stock traded as low as $11.04 and last traded at $11.12. 422,386 shares changed hands during trading, a decline of 88% from the average session volume of 3,386,532 shares. The stock had previously closed at $11.97.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on EBS shares. Rodman & Renshaw reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark upped their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Stock Down 9.0 %

The stock has a market capitalization of $590.06 million, a P/E ratio of -2.63 and a beta of 1.57. The stock has a fifty day moving average price of $8.50 and a 200 day moving average price of $7.89. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 0.54.

Institutional Trading of Emergent BioSolutions

A number of hedge funds have recently made changes to their positions in EBS. CWM LLC boosted its holdings in shares of Emergent BioSolutions by 32,706.7% during the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 4,906 shares during the last quarter. Tidal Investments LLC acquired a new stake in shares of Emergent BioSolutions during the first quarter worth $34,000. Meeder Asset Management Inc. purchased a new position in Emergent BioSolutions in the second quarter valued at $41,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Emergent BioSolutions in the first quarter valued at about $57,000. Finally, Price T Rowe Associates Inc. MD boosted its position in Emergent BioSolutions by 22.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 4,409 shares during the last quarter. 78.40% of the stock is owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.